Ron Squarer

Great insights! 🤔👏 ➡️ We prefer companies addressing large unmet needs and having clear paths to regulation. ➡️ High-potential areas - precision oncology and improving AI applications in drug development. ➡️ Companies need to prioritize pipeline positioning and leverage partnerships to attract investor interests. ➡️ Deep specialization in the underlying biology. 🧬🥼🧫 🔬 🧪 #biotech #lifescience #healthcare #therapeutics #startup #founders #precisiononcology #AIapplications #drugdevelopment #venturecapital

7

We are thrilled to announce that SciTech Development, Inc. has received an additional supply of fenretinide, a key pharmaceutical ingredient in our ST-001 investigational drug product and drug pipeline, from the National Cancer Institute (NCI). This critical provision enables SciTech to treat over 300 patients and accelerate the progress of their Phase 1a and 1b trials for relapsed or refractory T-cell non-Hodgkin lymphoma across six U.S. locations, as well as in other cancer indications. With this new supply, we’re taking a bold step forward in developing innovative cancer therapies that SciTech brings hope to those facing difficult-to-treat cancers. 🗓 Join Us for an Exclusive Opportunity: On Wednesday, October 9th at 1 PM EST, we are hosting SciTech’s CEO, Earle Holsapple III, for an insightful discussion on the latest developments. If you’d like to learn more or be a part of this event, send me a message and join us as we dive into the exciting future of SciTech’s cancer therapies. #SciTechDevelopment #CancerResearch #TCellLymphoma #Pharmaceuticals #Biotech #CancerInnovation #Investors #Phase1Trials #BiotechInnovation

11

3 Comments

Prof. Ehrlich, we found the targets for your magic bullets! We updated our video from three years ago and posted it on our new website, https://www.fbbbio.com. #venturecapital #angelinvestor #cancer #hivaids #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention OK

17

2 Comments

This is a really important discussion hosted by the American Society of Gene & Cell Therapy. In order to improve patient access to transformative #CGT medicines, we need to consider the downstream effects of how trial designs inform drug labels, which are later referenced by payers making reimbursement determinations that may ultimately exclude some patients. We need thoughtful drug development and evidence generation strategies in both the pre- and post-approval settings as a means of effectively expanding access. #ASGCTPatientEducation

27

Strategic vs. Private Equity In my recent webinar, I hosted Bryan Poltilove, former Operating Partner with BroadOak Capital Partners and VP/GM Cell & Gene Therapy at Thermo Fisher Scientific, to discuss raising capital with private equity and a strategic. In this segment, Bryan discusses strategic vs. private equity. For the full webinar, click the link in the comments. I'm committed to continuing this complimentary series and covering a variety of topics for leaders in the Life Science Tools and Molecular Diagnostics domains. If you would like to stay informed on future webinars, please send me a message with your contact information. #startups #lifesciences #lifesciencetools #biopharma 

6

1 Comment

We examined the CSOs of 25 preclinical platform biotech companies that recently launched and successfully entered the clinic.   We found that most of these leaders did not have prior CSO experience (~80%) and grew up in a Biotech environment.   Our findings suggest that the ability to drive success as the CSO of a platform Biotech company is not dependent on prior CSO experience.   If prior CSO experience is not a major driver of success, then what are the key success factors for these leaders? Stay tuned for Part 2 of our platform Biotech CSO success series to find out!

29

1 Comment

BIG NEWS FOR HORMONE HEALTH! Almost 2 years in the making, so proud of the Elix team for the completion of our second independent clinical trial focused on #PCOS (Polycystic Ovary Syndrome). Big shoutout to our medical advisors, our passionate team and most of all - our community members for your strength, resilience and belief in more sustainable approaches to our health and longevity. The clinical study assessed two of Elix's flagship products—Cycle Balance and Daily Harmony. These herbal supplements, rooted in 5,000 years of TCM research, target inflammation and hormone imbalances associated with PCOS. Results revealed that in a group of non-birth control users: * 89.3% of participants agreed that Elix Cycle Balance and Daily Harmony have helped to regulate their cycle.
 * 85.7% of participants agreed that they had fewer premenstrual and menstrual cramps after taking Elix Cycle Balance and Daily Harmony.
 * 71.4% of participants agreed that taking Elix Cycle Balance and Daily Harmony had improved their hormonal acne/breakouts and that they experienced fewer mood swings.
 The trial, conducted over six months, involved 70 participants with Polycystic Ovary Syndrome aged 18-36, divided into two groups: those using hormonal birth control (BC) and those not using it (No BC). Each participant was also diagnosed with PCOS and experienced symptoms such as irregular menstrual periods or the absence of menstrual periods and/ or excessive facial or body hair, thinning hair, hair loss on the scalp, oily skin, and or acne. Additionally, the majority of participants in the Clinical Study experienced improvements in the following symptoms: * Cycle regulation
 * Bloating
 * Fatigue
 * Mood swings
 * Anxiety
 * Sleep quality
 * Premenstrual and menstrual cramps
 * Hormonal acne/breakouts
 * Brain fog
 * Mental clarity
 * Focus
 * Weight gain
 * Unwanted facial / body hair
 * Fluid retention
 * Overall PMS symptoms
 * Overall PCOS symptoms
 * Overall health and wellbeing https://lnkd.in/eUjV7DkZ

232

29 Comments

I <3 Jon Campbell takeaways and agree completely! I'll also add that, regardless of commercial failures in the space, #digital #medicine is here to stay and is really the only hope we have of fixing a broken healthcare system. Additionally, we'll see #AI/ML increasingly being utilized in healthcare to advance early access and equity and improve outcomes.

3

Importance of Early Revenue - Raising Capital w/PE and a Strategic In my recent webinar, I hosted Bryan Poltilove, former Operating Partner with BroadOak Capital Partners and VP/GM Cell & Gene Therapy at Thermo Fisher Scientific, to discuss raising capital with private equity and a strategic. In this segment, Bryan discusses the importance of early revenue. For the full webinar, click the link in the comments. I'm committed to continuing this complimentary series and covering a variety of topics for leaders in the Life Science Tools and Molecular Diagnostics domains. If you would like to stay informed on future webinars, please send me a message with your contact information. #startups #lifesciences #lifesciencetools #biopharma 

1

1 Comment

November marks Alzheimer Disease Awareness Month, a time to reflect on the urgent need for innovative solutions to this devastating disease. Today, over 6.9 million Americans live with Alzheimer disease and this number is projected to double by 2060. The past year has seen significant progress with several #cellandgenetherapies emerging as a viable treatment to address this complex disease and rising prevalence. Advancements in several novel #genetherapies targeting genetic risk factors and promising #celltherapies have the potential to address key mechanisms or slow progression of the disease. The work is far from over, but with these advanced therapies moving through the clinical pipeline, there is a new hope for patients and families battling this devastating disease. 

12

1 Comment

Exciting top line results from the TANDEM study via NewAmsterdam Pharma Corporation! ➡️ With <30% of high-risk Americans achieving their LDL-C goals, a fixed-dose oral combination that reduces LDL-C by >50% will be a welcome addition to the toolbox if/when approved! ➡️ I also very much appreciate that they speak “goal” and not “threshold”. Hopefully that is a language that the American Heart Association can re-learn prior to the release of their 2026 Cholesterol guidelines. #LDL #LowerFasterLonger

19

At Windhaul, we are committed to propelling growth and success for small to mid-sized clinical stage biotech companies. Our mission is straightforward: to elevate the value of biotech firms and their programs with patients, healthcare providers, and investors. Windhaul distinguishes itself as a premium boutique consulting firm and provider of innovative flexible staffing solutions leveraging highly experienced professionals. We specialize in navigating dynamic global regulatory landscapes and integrating forward thinking commercial and market access insights into the strategic decision-making process. Our team consists of seasoned industry leaders, including former c-suite executives and functional heads, who bring invaluable hands-on leadership and management expertise throughout the journey of developing and approving new therapies. Clients choose Windhaul for our immediate effectiveness and capability to seamlessly integrate expert consultants into their teams on an interim or fractional basis. Whether guiding the clinical, regulatory, or commercial development of complex biologics or cutting-edge therapies such as cell and gene editing products, Windhaul excels across the entire product lifecycle. Let's collaborate to drive innovation and create enduring value together. #Biotech hashtag #RegulatoryAffairs hashtag #CommercialStrategy hashtag #MarketAccess hashtag #DrugDevelopment hashtag #BiotechConsulting hashtag #BiotechStaffing hashtag #BiotechInvesting https://www.windhaul.com/

37

It's official. 💫 David Kiewlich of BADASS Labs is now a partner of ours at Fruitionary Why is David joining us as a partner? 1. As many of you might know, it has been a dream of mine to build a biotech incubator. David owns two giant biotech incubators in the SF Bay Area, intending to open more soon, in different parts of the USA. 2. He cares a lot about startups and their growth, we share these values. He always makes himself available to consult with you. And, he wants to see you scale. 3. Our connection on shared goals was instant, and his advice/stories are inspirational. Among many stories, he shared with me how he struggled, working two jobs to get himself through Harvard University; and how in another story he opened a non-profit, started filling up a Toyota Prius with leftover food, and eventually distributed thousands of pounds of food to the homeless population of the Bay Area. These are three among many reasons that David will now be Advisor and Partner in Business Development for Fruitionary. @ Startups in Biotech, please keep building great companies, and we can help you grow! -Ali Darwish CEO & Founder Fruitionary #biotech #biotechgrowth #entrepreneurship #partnership #consulting #syntheticbiology #synbio #innovations

36

6 Comments

The Value of Alpha and Beta Testing In my recent webinar, I hosted Bryan Poltilove, former Operating Partner with BroadOak Capital Partners and VP/GM Cell & Gene Therapy at Thermo Fisher Scientific, to discuss raising capital with private equity and a strategic. In this segment, Bryan discusses alpha and beta testing. For the full webinar, click the link in the comments. I'm committed to continuing this complimentary series and covering a variety of topics for leaders in the Life Science Tools and Molecular Diagnostics domains. If you would like to stay informed on future webinars, please send me a message with your contact information. #startups #lifesciences #lifesciencetools #biopharma 

3

1 Comment

IPA Therapeutics/ImmunoPrecise Antibodies(NASDAQ: IPA $1.01) Incredible News Release IPA/BioStrand Team!!! Congratulations 💥 I am at a loss for words how the stock market is valuing this company at less than $30 million USD market capitalization? "Highly Specific Binding of Novel Antibodies to a Tumor Microenvironment Protein of Previously Unknown Structure - Verified in Laboratory Setting" "The Targeted Protein, Residing Within the Harsh Tumor Microenvironment Represents a Key Challenge in Healthcare and the Treatment of Cancers." This is Validation of the HYFT Technology and LENSai.......period!!!!!! Many other Companies dealing in Small Molecule AI Drug Discovery...yes Small Molecule have 20X, 50X+ the market cap??? This is not to mention 5 consecutive quarters of record revenue. Please complete your own due diligence to decide and stay tuned..... IPA (ImmunoPrecise Antibodies) BioStrand (a subsidiary of IPA) InterSystems hashtag #LENSai hashtag #Biotech hashtag #ai hashtag #HYFTs hashtag #HYFTTechnology hashtag #drugdiscovery hashtag #healthcare hashtag #pharma hashtag #personalizedmedicine hashtag #omics hashtag #AIDrugDiscovery hashtag #systemthinking hashtag #bioinformatics hashtag #antibodies hashtag #machinelearning hashtag #multiomics hashtag #LLMs hashtag #datascience hashtag #computationalbiology hashtag #nlp hashtag #ontologies hashtag #semantics hashtag #knowledgegraphs hashtag #lifesciences hashtag #bigdata hashtag #informationintegrationdilemma hashtag #patternrecognition hashtag #insilico hashtag #molecularbiologists hashtag #aminoacids hashtag #dna hashtag #rna hashtag #HYFTpatterns

19

Is Dyne Done? While Dyne's corporate website announces a positive spin on DMD clinical trial results, investors were not convinced by safety nor efficacy measures leading to stock drop. CBO, COO, and CMO now announced resignation, leaving the CEO to manage the executive team catastrophe. Regardless, the company will push forward towards registration, perhaps in hopes of receiving special benevolence from Peter Marks along the way... As I am not a specialist in DMD clinical measures, can anyone comment how does the Dyne outcome compares with Sarepta Exondys-51? https://lnkd.in/ey9RwXZF

29

5 Comments

In this position paper, Marc argues that #Oncology is the next therapeutic frontier for the application of value-based agreements. As a country and society, we must move towards value-based health - from therapeutics to the provisioning of healthcare services. Thought leaders like Peter have been discussing the societal value and importance of therapeutics for some time. It's now time to put our money where value is created, not destroyed. #NoPatientLeftBehind

2

Wow! Recursion Pharmaceuticals has agreed to buy Exscientia for $688 million in an all-stock deal, merging two leading AI-driven drug discovery platforms. This acquisition enhances Recursion's pipeline and partnerships, gaining assets from Exscientia, known for collaborations with Sanofi and Merck. The combined entity will have nearly $850 million in cash to advance treatments for rare diseases and cancer. Recursion aims to "make medicines better and faster" by leveraging Exscientia's AI drug discovery capabilities. This deal underscores AI's transformative role in revolutionizing the traditionally slow drug development process. I believe this powerful merger will yield exciting innovations in the coming years. https://lnkd.in/eUwRtnPn #Biotech #AI #DrugDiscovery #Innovation #Healthcare #Recursion #Exscientia

19

How do you make drug discovery better? Speed and efficiency is important, but predictability and certainty is game changing. That’s why we leverage the power of genetic chemistry to find better starting points for new small molecule drugs. Thank you Brian K. Buntz for delving into our Chemilogics platform, the drug leads we’ve found, and how our technologies and team are pushing the limits of what’s traditionally been thought possible in drug discovery. #Chemilogics #geneticchemistry #FlagshipFounded #drugdiscovery #smallmolecules #AI #machinelearning #metagenome

22

1 Comment